Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 05, 2022 16:01 ET
|
Mereo BioPharma Group plc
LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare...
Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
June 02, 2022 08:00 ET
|
Mereo BioPharma Group plc
--ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off-- --Etigilimab safe and well tolerated, no new safety signals-- ...
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
May 26, 2022 17:05 ET
|
Mereo BioPharma Group plc
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
May 26, 2022 16:30 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
May 17, 2022 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema
May 09, 2022 07:00 ET
|
Mereo BioPharma Group plc
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period ...
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
May 06, 2022 17:12 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology...
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
March 31, 2022 16:01 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022
March 03, 2022 08:30 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on...